- Home
- NXPL vs NXTC Comparison
NXPL vs NXTC Comparison
Compare NXPL & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPL | NXTC |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 24.8M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NXPL | NXTC |
|---|---|---|
| Price | $8.20 | $6.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 12.5K | ★ 63.2K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,869,558.00 | ★ $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.50 | N/A |
| 52 Week Low | $0.34 | $1.55 |
| 52 Week High | $9.94 | $15.74 |
Technical Indicators
Market Signals| Indicator | NXPL | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 54.58 |
| Support Level | $5.53 | $4.28 |
| Resistance Level | $8.37 | $8.68 |
| Average True Range (ATR) | 0.79 | 0.77 |
| MACD | -0.11 | 0.07 |
| Stochastic Oscillator | 8.74 | 67.04 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.